Ecnoglutide

Ecnoglutide (VRB-101) is a once-weekly oral GLP-1 receptor agonist being developed by Verdiva Bio for obesity and overweight with weight-related comorbidities. The Phase 2b trial, known publicly as EVOLVE-2 (NCT07281937), has completed enrollment at 206 patients across 22 US sites, with topline results guided for end of 2026 [1, 9]. Verdiva licensed the molecule from Sciwind Biosciences, which has published Phase 3 data in Chinese type 2 diabetes patients [2]. The commercial thesis must be reframed. As of December 22, 2025 the FDA approved oral Wegovy (semaglutide 25mg once-daily), and Novo Nordisk launched the pill in the US in early January 2026 [10]. Ecnoglutide is therefore not racing to become the first oral GLP-1 obesity therapy. It is entering a market with an approved daily oral (oral Wegovy, ~16.6% mean weight loss in OASIS 4), dominant weekly injectables (Wegovy injectable ~15%, Zepbound ~20%), and Lilly's small-molecule oral orforglipron (~12.4% at 72 weeks in ATTAIN-1) close behind [8, 10]. The differentiation now hinges on once-weekly oral versus once-daily oral, and whether that convenience gap actually moves the needle for patients when both options are pills is an open commercial question. To justify the pipeline story, ecnoglutide needs to approach oral Wegovy's efficacy while delivering weekly rather than daily dosing. The risk is not the biology but the formulation: making a peptide survive the gut well enough to work in a single weekly pill.

Investigational for obesity in the US and global markets (Verdiva holds rights outside greater China and South Korea). The Phase 2b obesity trial EVOLVE-2 (NCT07281937, n=206, Verdiva sponsor) has completed enrollment across 22 US sites, with topline data expected by end of 2026 [1, 9]. The parent molecule (developed by Sciwind Biosciences as XW003) has Phase 3 type 2 diabetes data published in Nature Communications from the EECOH-1 trial showing efficacy versus placebo, and has reportedly received Chinese NMPA approval for T2D in 2025 [2]. Two related studies are ongoing: a Phase 2 weight-maintenance study in patients who already achieved weight loss (NCT07553299, n=120) [3], and a Phase 1 combination with VRB-103 (an amylin-class asset) aimed at boosting efficacy (NCT07628127, n=336) [4]. No FDA breakthrough or fast-track designation has been publicly disclosed for the obesity program. Verdiva Bio launched in January 2025 with an oversubscribed $411M Series A co-led by Forbion and General Atlantic, with participation from RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital [5]. Timing: EVOLVE-2 readout in the second half of 2026, potentially within weeks to a few months as of August 2026; Phase 3 initiation would likely follow in 2027 if data support advancement.

GLP-1 is a gut hormone released after eating that tells the pancreas to release insulin and tells the brain the stomach is full. GLP-1 receptor agonists are drugs that mimic this hormone. The class has proven itself in obesity: injectable semaglutide (Wegovy) and tirzepatide (Zepbound) drive 15-20% body weight loss in Phase 3 trials, and as of January 2026 oral semaglutide (Wegovy pill, 25mg once-daily) is FDA-approved for obesity with ~16.6% mean weight loss in OASIS 4 [10]. Ecnoglutide is a modified peptide reportedly designed to preferentially trigger the cAMP signaling arm downstream of the receptor (cAMP, cyclic AMP, is a molecular messenger inside cells that turns on processes such as insulin release and appetite suppression) rather than the β-arrestin arm (a second signaling pathway hypothesized in the field to drive side effects without adding efficacy). This is a design rationale rather than a clinically demonstrated advantage. The published Phase 3 EECOH-1 [2] does not report a validated GI side-effect benefit attributable to biased agonism, and ecnoglutide-specific human pharmacology data confirming differentiated signaling in patients has not been published. At the receptor level the target is as validated as any in medicine, backed not by animal models but by billions in real-world revenue and hundreds of thousands of patients treated. The novelty here is not the target but the delivery. Semaglutide, exenatide, liraglutide, and dulaglutide were injectables for years because peptide drugs get chewed up by stomach acid and gut enzymes. Oral Rybelsus and now oral Wegovy use the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier molecule added to the pill that helps the peptide cross the gut wall), but dosing remains daily on an empty stomach. Ecnoglutide's weekly oral profile, if it holds up in EVOLVE-2, would be a first-in-class dosing schedule for a GLP-1RA pill in obesity.

EVOLVE-2 (NCT07281937) is a Phase 2b dose-finding study of weekly oral ecnoglutide versus placebo in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The trial enrolled 206 participants across 22 US sites, with five active dose arms plus placebo, dosed once-weekly for 20 weeks [1, 9]. The primary endpoint is mean percent change from baseline in body weight, the same endpoint that anchored the STEP and SURMOUNT programs and the number payers and physicians actually care about. What the study does not appear to include is an active comparator arm against either injectable semaglutide or the newly approved oral Wegovy, which would be the honest head-to-head. A placebo win at Phase 2b is expected for any working GLP-1RA; the more interesting number will be the placebo-adjusted weight loss at 20 weeks, and how it compares to oral Wegovy's ~16.6% at 68 weeks in OASIS 4 and orforglipron's ~12.4% at 72 weeks in ATTAIN-1 [8, 10]. Duration is materially shorter than the pivotal comparators, so cross-trial comparison requires caution. A parallel Phase 2 (NCT07553299) is testing the drug for weight maintenance after initial loss [3], a smart differentiation given the well-documented concern that patients regain weight after stopping GLP-1s. The combination Phase 1 with VRB-103 (NCT07628127) is the earliest signal of a two-hormone strategy borrowed from Lilly's tirzepatide playbook [4].

Our model estimates a 9% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, heavier-than-usual blinding, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk sits first, and the bar is higher than an injectable-only comparison suggests. If ecnoglutide delivers only 5-8% weight loss versus oral Wegovy's ~16.6% (OASIS 4, 68 weeks) [10], orforglipron's ~12.4% (ATTAIN-1, 72 weeks) [8], injectable semaglutide's ~15%, and tirzepatide's ~20%, it becomes a hard sell regardless of weekly dosing convenience. Payers are already pushing back on obesity drug coverage; a weaker product gets formulary-blocked (a formulary is the list of drugs a health insurer agrees to cover, so drugs left off require patients to pay full price or go without). To be investable in the presence of an approved daily oral, ecnoglutide plausibly needs to land within roughly 3-4 percentage points of oral Wegovy on placebo-adjusted weight loss, or show a clean tolerability advantage. Safety risk is class-standard: GI side effects (nausea, vomiting, diarrhea) drive high discontinuation rates across all GLP-1RAs. Any signal of pancreatitis, thyroid C-cell effects, or gallbladder events at higher-than-class rates would be a program killer, and the drug-drug interaction studies published so far cover only warfarin, metformin, rosuvastatin, and digoxin [6, 7], leaving a long tail of untested combinations. Formulation risk is somewhat unique: oral peptide absorption is inconsistent between patients and even between doses in the same patient. If EVOLVE-2 shows high variability in exposure, the label will reflect that and physicians will hesitate. Competitive risk is severe. Novo Nordisk already sells oral Wegovy with global manufacturing scale and brand recognition [10], and Lilly's orforglipron is a small-molecule oral GLP-1RA that is far easier to formulate and mass-produce and posted 12.4% weight loss in ATTAIN-1 in August 2025 [8]. Capital risk also matters: obesity Phase 3 programs typically run $500M to $1B+, versus Verdiva's $411M Series A [5]. Even with careful spend, Verdiva likely needs a partner or a further raise before pivotal trials.

Worth watching, urgently. The single data point that matters is the EVOLVE-2 Phase 2b topline weight loss, guided by Verdiva for end of 2026 [1, 9]. As of August 2026, that readout could be weeks to a few months away, and this is a near-term binary catalyst that investors typically act on before the announcement, not after. Two thresholds define the outcome, calibrated to a market that now includes an approved oral competitor. Placebo-adjusted weight loss below roughly 10% at 20 weeks means ecnoglutide is a second-tier oral option and the pipeline story deflates. Above roughly 12-13% (approaching oral Wegovy's OASIS 4 trajectory and beating orforglipron) means Verdiva has a genuinely competitive product to take into Phase 3. The differentiation pitch must survive contact with an already-approved daily oral: weekly-versus-daily is a real convenience factor but nowhere near the magnitude of pill-versus-injection. Verdiva is well-capitalized (the $411M Series A in January 2025 was co-led by Forbion and General Atlantic [5]) and staffed by executives from Novartis and Novo Nordisk who know this therapeutic space, so sponsor execution risk is lower than typical Series-A-stage biotech. However, obesity Phase 3 costs commonly run $500M to $1B+, so partnership or additional funding is likely required before pivotal trials. The parent company Sciwind Biosciences retained China rights and has already demonstrated regulatory competence there with EECOH-1 [2]. Open questions ahead of readout: which dose levels EVOLVE-2 tested and whether they are competitive with Novo's 25mg oral Wegovy, what IP protection Verdiva holds around its proprietary oral delivery technology and how it stacks up against Sciwind's retained China rights, and whether Verdiva has a partnership discussion ready to activate if data are strong. If the topline lands well, the follow-up questions become how fast Verdiva can start Phase 3 and whether they seek a Big Pharma partner versus going alone. If it lands poorly, the story shifts to whether the VRB-103 combination can rescue the platform, which is a much longer bet.